REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Feb 4, 2015 → Jul 23, 2018
NCT ID
NCT02265952About REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02265952. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02265952 | Phase 2 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia